Adverse effects of GPO-VIR to Blood Cells of the PLHA in the BMA General Hospital

Abstract

Adverse effects of GPO-VIR to Blood Cells of the PLHA in the BMA General Hospital

Supaporn           Karalak                             MD*

Lertlak               Leelaruangsang              MD**

*Blood Bank Department, BMA General Hospital

**Out-patient Department, BMA General Hospital

Objective: To determine the adverse effects of GPO-VIR (Drug combination of Stavudine, Lamivudine and Nevirapine) to blood cells of the patients living with HIV antigens (PLHA) in the BMA General Hospital.

Study design: Descriptive study.

Subjects: Fifty PLHA enrolled the Access To Care (ATC) project during May 2003-January 2004 , were treated with GPO-VIR in the out- patient clinic, Department of Medicine, BMA General Hospital.

Methods: Sex, age, body weight, CD4 cell count and CBC (complete blood count) in the record of ATC project were collected and analyzed.

Main outcome measures: Hematocrit, absolute neutrophil count (ANC), platelet count and CD4 cell count

Results: After continuous treatment with GPO-VIR for one year, adverse effects to blood cells were not occurred in all subjects. Hematocrit, absolute neutrophil count and CD4 cell count were increased significantly.

Conclusion: The adverse effects of GPO-VIR to blood cells (red blood cells, white blood cells and platelets) were not found in this study. The GPO-VIR was less bone marrow suppression. Hematocrit and absolute neutrophil count were increased significantly.

Key words: GPO-VIR, Stavudine, Lamivudine, Nevirapine, bone marrow suppression.

Vajira Med J 2005 ; 49 : 69 - 75